"Feedback"-Suppression of food-induced GLP-1 secretion by increasing of the intact GLP-1, DPP-4 inhibition: A comparison of Sitagliptin and Vildagliptin ["Feed-Back"-Suppression der Nahrungs-induzierten GLP-1-Sekretion durch Erhöhung des intakten GLP-1 unter DPP-4-Inhibition: Ein Vergleich von Vildagliptin und Sitagliptin]

Trial Profile

"Feedback"-Suppression of food-induced GLP-1 secretion by increasing of the intact GLP-1, DPP-4 inhibition: A comparison of Sitagliptin and Vildagliptin ["Feed-Back"-Suppression der Nahrungs-induzierten GLP-1-Sekretion durch Erhöhung des intakten GLP-1 unter DPP-4-Inhibition: Ein Vergleich von Vildagliptin und Sitagliptin]

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2014

At a glance

  • Drugs Vildagliptin (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 21 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top